Outcome of Board Meeting: Unaudited Financial results as of 30th June 2026.

29th July 2026 The Manager-Listing the Manager- Listing BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Bandra (E) Mumbai-400001 Mumbai-400051 BSE Code-537291 NSE Code-NATHBIOGEN Sub - Outcome of Board Meeting. Ref – Regulation 30 and Regulation 33 and Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements). We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on Wednesday, 29th July 2026, has approved the following. Pursuant to above-referred regulations, we enclose the following documents. 1. Statement of unaudited Standalone financial results, for the quarter ended 30th June 2026. (Annexure-I). 2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure- II). 3. Statement of unaudited Consolidated financial results, for the quarter ended 30th June 2026. (Annexure-III). 4. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure- IV). 5. Approved and fix the date of 33rd Annual General Meeting of the Company to be held on Thursday, 24th September 2026 at 11:00 a.m. through video conference/other audio-visual means accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The procedure for participation in the Annual General Meeting and book closure and record date will be intimated separately. The Meeting Commenced on 01:00 p.m. and concluded on 04:00 p.m. You are requested to take the above information on record. Thanking You Yours faithfully, For Nath Bio-Genes (India) Limited, Amol Gupta Chief Financial Officer iw !fiJ@ N”] >e€ DS Nath Bio-Genes (1) L¢d. (CIN LOTNIOMH1003PLC072842) STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 3 MONTHS ENDED 30/06/2026 Rs in Lakhs SR. i Quarter Ended Three Months Ended Year Ended No. Particulars 30-06-2026 31-03-2026 30-06-2025 30-06-2026 30-06-2025 31-03-2026 Unaudited Audited Unaudited Unaudited Unaudited Audited I/Income from operations (a) Revenue from operations 32284.28 4569.36 28017.18 32284.28 28017.18 43159.72 (b) Other Operating Income 0.00 0.00 0.00 0.00 0.00 0.00 Total Income 32284.28 4569.36 28017.18 32284.28 28017.18 43159.72 Il{fExpenses a) Production & Seed Conditioning Expenses 11001.14 6770.30 10824.23 11001.14 10824.23 29768.84 b) Purchase of Stock-in-Trade 122.90 186.99 435.33 122.90 435.33 752.09 c) Change in Inventories of Produced and Traded Goods 4875.21 (5661.54) 2379.62 4875.21 2379.62 (11388.72) d) Employee Benefit Expense 1036.03 347.86 905.17 1036.03 905.17 3333.33 e) Depreciation & Amortisation Expenses 100.50 102.29 97.50 100.50 97.50 394.79 f) Selling & Distribution Expenses 10797.45 1400.93 9569.91 10797.45 9569.91 12177.26 g) Other Expenses 944 .06 863.57 912.69 944 .06 912.69 3263.29 Total Expenscs 28877.29 4010.39 25124.44 28877.29 25124.44 38300.88 2 TR R afore ettier Bose]. s 558.97 2892.74 3406.99 2892.74 4858.84 finance cost and Exceptional Items (I-11) IV|Other Income 190.05 237.50 176.45 190.05 176.45 781.00 g Lot o Shtlancy ietivition betore fmmen 3597.04 796.47 3069.19 3597.04 3069.19 5639.84 cost and Exceptional Items (llI+IV) VI|Finance Cost 379.25 293.51 288.96 379.25 288.96 1330.69 VII|Profit from Ordinary Activities after Finance cost (V-VI) 3217.79 502.96 2780.23 3217.79 2780.23 4309.15 VIIl|Exceptional ltems Income/(Expenses) 119.98 125.79 206.34 119.98 206.34 600.73 IX|Profit from Ordinary Activities before Tax (VII-VIII) 3337.77 628.75 2986.57 3337.77 2986.57 4909.88 X|Tax Expense (a) Current Tax 72.09 233.06 65.97 72.09 65.97 450.42 (b) Earlier Year Tax 0.00 16.89 0.00 0.00 0.00 16.89 (c) Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 XI|Net Profit from Ordinary Activies after Tax (IX-X) 3265.68 378.80 2920.60 3265.68 2920.60 4442.57 XIl|Extra Ordinary Items (Net of Tax) 0.00 0.00 0.00 0.00 0.00 0.00 XIIl|Net Profit for the period (XI-XII) 3265.68 378.80 2920.60 3265.68 2920.60 4442.57 XIV|Other Comprehensive Income L;s.s(a) ltems that will not be reclassified to Profit or (1.75) 0.73 (1.50) (1.75) (1.50) (4.17) (b) Income tax relating to items that will not be reclassified to Profit or Loss 0.00 0.00 0.00 0.00 0.00 0.00 O2( a) Items that will be reclassified to Profit or 4.00 32.99 (6.50) 400 (6.50) 11.99 (b) Income tax relating to items that will be reclassified to Profit or Loss 0.00 0.00 0.00 0.00 Q00 Do Total other Comprehensive Income 2.25 33.72 (8.00) 225 (8.00) 7.82 XV|Total Comprehensive Income for the period (XIIl + XIV) 3267.93 412,52 2912.60 3267.93 2912.60 4450.39 XVI|Paid Up Equity Share Capital (Face Value Rs. 10/- cach) 1900.40 1900.40 1900.40 1900.40 1900.40 1900.40 XVIl|Reserve & Surplus 67036.62 VIl iasri:ilflg;er share (of Rs 10/- each) (not annualised) Basic 17.18 1.99 15.37 17.18 15.37 23.38 Notes: Please refer attached sheet FOR GAUTAM N ASSOClA Oé\\ CHARTERED ACC % ARTERED \ 7 NTANTS | M GAUTA A TH Bp-GENES (INDIA) LTD UDIN'-260 ) Place : Chhatrapati Sambhajinagar 26 Blqkmegoizw sATISH KAGLIWAL Date :29 July 2026 MANAGING DIRECTOR DIN 00119601 Regd. Office : Nath House, Nath Road, Chhatrapati Sambhajinagar - 431005 (MS) www.nathbiogenes.com NATH SE€EDS” Bio-Genes (i) Ltd. (CIN LO1110MH1993PLC072842) NOTES TO UNAUDITED STANDALONE RESULTS FOR THE QUARTER & 3 MONTHS ENDED ON 30/06/2026 1. The financial results were reviewed by the Audit Committee on 28 July 2026 and were thereafter approved by the Board of Directors at its meeting held on 29 July 2026. 2. The short provision of Schemes of Rs. 900.00 Lakhs pertaining to the quarter ending June 2025, as reported in the quarterly results of March 26 is now considered and represented in the results of June 2025. 3. The company deals with only one major product segment of Seed Cultivation. Thus, segmental reporting is not provided. 4. Investor Complaints: a. Received during the quarter - NIL b. Pending at the end of quarter— NIL 5. The figures have been regrouped/rearranged, wherever necessary. FOR GAUTAM N ASSOCIATES 75 CHARTERED ACCOUNTANTS /e =250 » Satish Kagliwal (Partner) v % J* Managing Director UDIN: 960327422 KBETO 5 P GA® DIN: 00119601 Place: Chhatrapati Sambhaji Nagar Date: 29 July 2026 Gautam N Associates Chartered Accountants 30, GNA House, Behind ABC Complex, Manmandir Travels Lane, Adalat Road, Aurangabad - 431 001 INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED The Board of Directors Nath Bio-Genes (India) Limited Chhatrapati Sambhajinagar (Aurangabad) 1. We have reviewed the accompanying standalone statement of unaudited financial results of Nath Bio-Genes (India) Limited (CIN : LO1110MH1993PLC072842) for the quarter ended 30" June 2026 and year to date results for the period 15 April 2026 to 30" June 2026 (‘The Statement’) being submitted by the Company pursuant to the requirements cf regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified. 2. This standalone statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- ‘Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review. 3. We conducted our review of the standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard re [Showing first 8,000 characters — download PDF for full document]